1. Home
  2. WGRX vs IMNN Comparison

WGRX vs IMNN Comparison

Compare WGRX & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wellgistics Health Inc.

WGRX

Wellgistics Health Inc.

HOLD

Current Price

$2.95

Market Cap

7.1M

Sector

Health Care

ML Signal

HOLD

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$1.90

Market Cap

8.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WGRX
IMNN
Founded
2022
1982
Country
United States
United States
Employees
N/A
N/A
Industry
Other Pharmaceuticals
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.1M
8.4M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
WGRX
IMNN
Price
$2.95
$1.90
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
27.0K
49.1K
Earning Date
05-21-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.07
$0.48
52 Week High
$4.49
$9.32

Technical Indicators

Market Signals
Indicator
WGRX
IMNN
Relative Strength Index (RSI) 51.60 42.38
Support Level $2.81 N/A
Resistance Level $3.87 $2.50
Average True Range (ATR) 0.27 0.15
MACD -0.17 0.03
Stochastic Oscillator 16.04 46.67

Price Performance

Historical Comparison
WGRX
IMNN

About WGRX Wellgistics Health Inc.

Wellgistics Health Inc is a healthcare technology and pharmaceutical logistics company. It simplifies the logistics of prescription fulfillment from the manufacturer and provider to the patient. The company seeks to be a micro health ecosystem, with a portfolio comprising a pharmacy, wholesale operations, and a technology division that provides a novel platform for hub and clinical services. It is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

Share on Social Networks: